Some additional cytogenetic aberrations in patients treated with Imatinib (STI571)

被引：0
|
作者：
Salamanczuk, Z. [1 ]
Jakobczyk, M. [1 ]
Sacha, T. [1 ]
Skotnicki, A. B. [1 ]
机构：
[1] Jagiellonian Univ, Dept Haematol, PL-31007 Krakow, Poland
来源：
CHROMOSOME RESEARCH | 2005年 / 13卷
关键词：
D O I：
暂无
中图分类号：
Q5 [生物化学]; Q7 [分子生物学];
学科分类号：
071010 ; 081704 ;
摘要：
引用
收藏
页码：171 / 171
页数：1
相关论文
共 50 条
  • [31] Effect of Imatinib (STI571) on Metastatic Gastrointestinal Stromal Tumors: Report of a Case
    Yuichi Ando
    Takuya Tsunoda
    Yoshifumi Beck
    Takuya Takayama
    Hideaki Tahara
    Surgery Today, 2005, 35 : 157 - 160
  • [32] Morphologic and cytogenetic effects of imatinib (STI571) on the bone marrow and blood of patients with Philadelphia chromosome (Ph) positive chronic myeloid leukaemia (CML).
    McNamara, CJ
    Grigg, AP
    Szer, J
    Roberts, A
    Lynda, C
    Hoyt, TR
    Lynch, K
    Juneja, S
    BLOOD, 2001, 98 (11) : 263B - 263B
  • [33] Tyrosine kinase inhibitor imatinib (STI571) as an anticancer agent for solid tumours
    Joensuu, H
    Dimitrijevic, S
    ANNALS OF MEDICINE, 2001, 33 (07) : 451 - 455
  • [34] Effect of imatinib (STI571) on metastatic gastrointestinal stromal tumors: Report of a case
    Ando, Y
    Tsunoda, T
    Beck, Y
    Takayama, T
    Tahara, H
    SURGERY TODAY, 2005, 35 (02) : 157 - 160
  • [35] Imatinib mesylate (STI571) in CML patients after autologous peripheral blood stem cell transplantation
    Mahmoud, HK
    El-Emary, M
    Nazier, AA
    El-Haddad, A
    Fahmy, OA
    El-Sayed, N
    AbdMooti, M
    Nasser, A
    Sobhy, A
    El-Nahass, Y
    BONE MARROW TRANSPLANTATION, 2006, 37 : S231 - S231
  • [36] Molecular monitoring of complete cytogenetic responders following treatment with imatinib (STI571, Gleevec) for CML: A report from the UKSTI571 study group.
    Feng, L
    Drummond, MW
    Byrne, J
    Shepherd, PCA
    Apperley, JF
    O'Brien, SG
    Craddock, CF
    Clark, RE
    Cervantes, F
    Lennard, AL
    Holyoake, TL
    Szydlo, RM
    Goldman, JM
    Kaeda, JS
    BLOOD, 2002, 100 (11) : 368A - 368A
  • [37] Marrow morphology of chronic myelogenous leukemia in patients treated with imatinib mesylate (Gleevac, Sti-571): Correlation with cytogenetic response
    Racke, F
    Allan, RW
    Miller, C
    Weir, EG
    LABORATORY INVESTIGATION, 2005, 85 : 248A - 248A
  • [38] Marrow morphology of chronic myelogenous leukemia in patients treated with imatinib mesylate (Gleevac, Sti-571): Correlation with cytogenetic response
    Racke, F
    Allan, RW
    Miller, C
    Weir, EG
    MODERN PATHOLOGY, 2005, 18 : 248A - 248A
  • [39] STI571 (IMATINIB): STRUCTURAL AND ENZYMATIC STUDIES OF INTERACTIONS WITH ABL KINASE AND RESISTANCE MUTANTS
    Cowan-Jacob, S. W.
    Fendrich, G.
    Guez, V.
    Liebetanz, J.
    Fabbro, D.
    Manley, P. W.
    ACTA CRYSTALLOGRAPHICA A-FOUNDATION AND ADVANCES, 2002, 58 : C289 - C289
  • [40] Activity of Glivec (imatinib mesylate, STI571) in a patient with Ph plus CML accelerated phase and additional chromosomic abnormalities.
    Conchon, M
    Dias, L
    Velloso, E
    Bendit, I
    Santina, G
    Chamone, DF
    Dorlhiac-Llacer, P
    BLOOD, 2001, 98 (11) : 256B - 256B
12345